WHAT IS CLAIMED IS:

1. A compound of structural formula I:



(I)

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from:

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) $-OR^a$,
(4) $-NR^aR^b$,
(5) $-NR^bC(O)R^a$,
(6) $-CO_2R^a$,
(7) $-C(O)NR^aR^b$,
(8) cyano,
(9) $-SR^b$, and
(10) $-SO_2R^b$;

R^2 is selected from:

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) $-OR^a$,
(4) $-NR^aR^b$,
(5) $-NR^aC(O)R^b$,
(6) $-CO_2R^a$,
(7) $-C(O)NR^aR^b$,
(8) cyano,
(9) $-SR^a$, and
(10) $-SO_2R^a$;

R^3 is selected from:

(1) aryl, and

(2) heteroaryl,

wherein each aryl and heteroaryl is optionally substituted with one to four substituents independently selected from Rg;

R^4 is selected from:

(1) aryl, and

(2) heteroaryl,

wherein each aryl and heteroaryl is optionally substituted with one to four substituents independently selected from Rg;

each R^a is independently selected from:

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) C_{2-10} alkenyl,
(4) cycloalkyl,
(5) cycloalkyl-C_{1-10}alkyl;
(6) cycloheteroalkyl,
(7) cycloheteroalkyl-C_{1-10} alkyl;
(8) aryl,
(9) heteroaryl,
(10) aryl-C_{1-10}alkyl, and
(11) heteroaryl-C_{1-10}alkyl; and

each R^b is independently selected from:

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) C_{2-10} alkenyl,
(4) cycloalkyl,
(5) cycloalkyl-C_{1-10}alkyl;
(6) cycloheteroalkyl,
(7) cycloheteroalkyl-C_{1-10} alkyl;
(8) aryl,
(9) heteroaryl,
(10) aryl-C_{1-10}alkyl, and
(11) heteroaryl-C_{1-10}alkyl, or

R^a and R^b together with the nitrogen atom to which they are attached form a bridged or unbridged heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R^d,

each R^a and R^b may be unsubstituted or substituted with one to three substituents selected from R^c;

each R^c is independently selected from:

(1) C_{1-10}alkyl,
(2) $-OR^d$,
(3) $-NR^eS(O)_mR^d$,
(4) halogen,
(5) $-SR^d$,
(6) $-S(O)_mNR^dR^e$,
(7) $-NR^dR^e$,
(8) $-C(O)R^d$,
(9) $-CO_2R^d$,
(10) -CN,
(11) $-C(O)NR^dR^e$,
(12) $-NR^eC(O)R^d$,
(13) $-NR^eC(O)OR^de$,
(14) $-NR^eC(O)NR^dR^e$,
(15) $-CF_3$,
(16) $-OCF_3$,
(17) cycloheteroalkyl,
(18) aryl,
(19) arylC_{1-4}alkyl,
(20) heteroaryl, and
(21) heteroarylC_{1-4}alkyl;

R^d and R^e are independently selected from:

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) C_{2-10} alkenyl,
(4) cycloalkyl,
(5) cycloalkyl-C_{1-10}alkyl;
(6) cycloheteroalkyl,
(7) cycloheteroalkyl-C_{1-10} alkyl;
(8) aryl,
(9) heteroaryl,
(10) aryl-C_{1-10}alkyl, and

(11) heteroaryl-C_{1-10}alkyl, or

R^d and R^e together with the nitrogen atom to which they are attached form a bridged or unbridged heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R^f,

each R^d and R^e may be unsubstituted or substituted with one to three substituents selected from R^f;

R^f is independently selected from:

(1) halogen,
(2) C_{1-10}alkyl,
(3) -O-C_{1-4}alkyl,
(4) –S-C_{1-4}alkyl,
(5) -CN,
(6) -CF_3, and
(7) -OCF_3;

each Rg is independently selected from:

(1) halogen,
(2) C_{1-10}alkyl,
(3) -O-C_{1-4}alkyl,
(4) –S-C_{1-4}alkyl,
(5) -CN,
(6) -CF_3, and
(7) -OCF_3; and

m is selected from 1 and 2.

2. The compound according to Claim 1, wherein: R^3 and R^4 are each independently selected from:

(1) phenyl,
(2) pyridyl,

wherein each phenyl and pyridyl is optionally substituted with one to three substituents independently selected from Rg;

and pharmaceutically acceptable salts thereof.

3. The compound according to Claim 1, wherein R^3 and R^4 are each independently selected from:

(1)  ,

(2)  ,

(3)  , and

(4)  ;

and pharmaceutically acceptable salts thereof.

4. The compound according to Claim 1, wherein:

R^1 is selected from:

(1) C_{1-6}alkyl,

(2) –OH,

(3) -OC_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,

(4) cycloalkyloxy-, unsubstituted or substituted with one to three R^c substituents,

(5) cycloalkyl-C_{1-4}alkyloxy-, unsubstituted or substituted with one to three R^c substituents,

(6) cycloheteroalkyloxy-, unsubstituted or substituted with one to three R^c substituents,

(7) cycloheteroalkyl-C_{1-4} alkyloxy, unsubstituted or substituted with one to three R^c substituents,

(8) phenyloxy, unsubstituted or substituted with one to three R^c substituents,

(9) heteroaryloxy, unsubstituted or substituted with one to three R^c substituents,

(10) phenyl-C_{1-4}alkyloxy, unsubstituted or substituted with one to three R^c substituents,

(11) heteroaryl-C_{1-4}alkyloxy, unsubstituted or substituted with one to three R^c substituents,

(12) -NR^aR^b,
(13) -$NR^bC(O)R^a$,
(14) -CO_2H,
(15) C_{1-6}alkyloxycarbonyl-, unsubstituted or substituted with one to three R^c substituents,
(16) cycloalkyloxycarbonyl-, unsubstituted or substituted with one to three R^c substituents,
(17) cycloalkyl-C_{1-4}alkyloxycarbonyl-, unsubstituted or substituted with one to three R^c substituents,
(18) phenyloxycarbonyl, unsubstituted or substituted with one to three R^c substituents,
(19) heteroaryloxycarbonyl, unsubstituted or substituted with one to three R^c substituents,
(20) phenyl-C_{1-4}alkyloxycarbonyl, unsubstituted or substituted with one to three R^c substituents,
(21) heteroaryl-C_{1-4}alkyloxycarbonyl, unsubstituted or substituted with one to three R^c substituents,
(22) -$C(O)NR^aR^b$,
(23) cyano,
(24) –SC_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,
(25) –SO_2C_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents; and

R^a and R^b are each selected from:
(1) hydrogen,
(2) C_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,
(3) cycloalkyl, unsubstituted or substituted with one to three R^c substituents,
(4) cycloalkyl-C_{1-4}alkyl, unsubstituted or substituted with one to three R^c substituents,
(5) phenyl, unsubstituted or substituted with one to three R^c substituents,
(6) heteroaryl, unsubstituted or substituted with one to three R^c substituents,
(7) phenyl-C_{1-4}alkyl, unsubstituted or substituted with one to three R^c substituents, or
(8) heteroaryl-C_{1-4}alkyl, unsubstituted or substituted with one to three R^c substituents, or

when bonded to nitrogen, R^a and R^b together with the nitrogen atom to which they are attached form a bridged or unbridged heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R^d, unsubstituted or substituted on carbon with one to three R^c substitutents;

and pharmaceutically acceptable salts thereof.

5. The compound according to Claim 4, wherein R^1 is selected from:

(1) C_{1-6}alkyl,

(2) –OH,

(3) -OC_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,

(4) C_{4-7}cycloalkyloxy-, unsubstituted or substituted with one to two R^c substituents,

(5) cycloalkyl-C_{1-3}alkyloxy-, unsubstituted or substituted with one to two R^c substituents,

(6) phenyloxy, unsubstituted or substituted with one to two R^c substituents,

(7) pyridyloxy, unsubstituted or substituted with one to two R^c substituents,

(8) phenyl-C_{1-3}alkyloxy, unsubstituted or substituted with one to two R^c substituents,

(9) pyridyl-C_{1-3}alkyloxy, unsubstituted or substituted with one to two R^c substituents,

(10) -NR^aR^b, wherein:

R^a is selected from:

(a) hydrogen,

(b) C_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,

(c) cycloalkyl, unsubstituted or substituted with one to two R^c substituents,

(d) cycloalkyl-C_{1-4}alkyl, unsubstituted or substituted with one to two R^c substituents,

(e) phenyl, unsubstituted or substituted with one to two R^c substituents,

(f) heteroaryl, unsubstituted or substituted with one to two R^c substituents,

(g) benzyl, unsubstituted or substituted with one to two R^c substituents,

R^b is selected from:

(a) hydrogen,

(b) C_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,

or

R^a and R^b together with the nitrogen atom to which they are attached form a bridged or unbridged heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R^d, unsubstituted or substituted on carbon with one to two R^c substitutents,

(11) -$NR^bC(O)R^a$, wherein:

R^a is selected from:

(a) hydrogen,

(b) C_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,

(c) cycloalkyl, unsubstituted or substituted with one to two R^c substituents,
(d) cycloalkyl-C_{1-4}alkyl, unsubstituted or substituted with one to two R^c substituents,
(e) phenyl, unsubstituted or substituted with one to two R^c substituents,
(f) pyridyl, unsubstituted or substituted with one to three R^c substituents,
(g) benzyl, unsubstituted or substituted with one to two R^c substituents,
(h) pyridylmethyl-, unsubstituted or substituted with one to three R^c substituents,

R^b is selected from:
(a) hydrogen,
(b) C_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,
(12) $-CO_2H$,
(13) C_{1-6}alkyloxycarbonyl-, unsubstituted or substituted with one to three R^c substituents,
(14) $-C(O)NR^aR^b$, wherein:
R^a is selected from:
(a) hydrogen,
(b) C_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,
R^b is selected from:
(a) hydrogen, and
(b) C_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,
(15) cyano
(16) $-SC_{1-6}$alkyl, unsubstituted or substituted with one to three R^c substituents, and
(17) $-SO_2C_{1-6}$alkyl, unsubstituted or substituted with one to three R^c substituents;

each R^c is independently selected from:
(1) C_{1-3}alkyl,
(2) hydroxy,
(3) $-OC_{1-3}$alkyl ,
(4) halogen,
(5) $-SCH_3$,
(6) –SH,
(7) $-NR^dR^e$,
(8) $-C(O)C_{1-3}$alkyl,
(9) $-CO_2C_{1-3}$alkyl,
(10) $-CO_2H$,

(11) -CN,
(12) $-CF_3$,
(13) $-OCF_3$,
(14) cycloheteroalkyl,
(15) phenyl,
(16) benzyl, and
(17) pyridyl;

and pharmaceutically acceptable salts thereof.

6. The compound according to Claim 4, wherein R^2 is selected from:

(1) hydrogen,
(2) C_{1-6}alkyl,
(3) –OH,
(4) $-OC_{1-6}$alkyl, unsubstituted or substituted with one to three R^c substituents,
(5) cycloalkyloxy-, unsubstituted or substituted with one to three R^c substituents,
(6) cycloalkyl-C_{1-4}alkyloxy-, unsubstituted or substituted with one to three R^c substituents,
(7) cycloheteroalkyloxy-, unsubstituted or substituted with one to three R^c substituents,
(8) cycloheteroalkyl-C_{1-4} alkyloxy, unsubstituted or substituted with one to three R^c substituents,
(9) phenyloxy, unsubstituted or substituted with one to three R^c substituents,
(10) heteroaryloxy, unsubstituted or substituted with one to three R^c substituents,
(11) phenyl-C_{1-4}alkyloxy, unsubstituted or substituted with one to three R^c substituents,
(12) heteroaryl-C_{1-4}alkyloxy, unsubstituted or substituted with one to three R^c substituents,
(13) $-NR^aR^b$,
(14) $-NR^bC(O)R^a$,
(15) $-CO_2H$,
(16) C_{1-6}alkyloxycarbonyl-, unsubstituted or substituted with one to three R^c substituents,
(17) cycloalkyloxycarbonyl-, unsubstituted or substituted with one to three R^c substituents,

(18) cycloalkyl-C_{1-4}alkyloxycarbonyl-, unsubstituted or substituted with one to three R^c substituents,
(19) phenyloxycarbonyl, unsubstituted or substituted with one to three R^c substituents,
(20) heteroaryloxycarbonyl, unsubstituted or substituted with one to three R^c substituents,
(21) phenyl-C_{1-4}alkyloxycarbonyl, unsubstituted or substituted with one to three R^c substituents,
(22) heteroaryl-C_{1-4}alkyloxycarbonyl, unsubstituted or substituted with one to three R^c substituents,
(23) -$C(O)NR^aR^b$,
(24) cyano,
(25) –SC_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents, and
(26) –SO_2C_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,

and pharmaceutically acceptable salts thereof.

7. The compound according to Claim 1, wherein:

R^2 is selected from:

(1) hydrogen,
(2) C_{1-6}alkyl,
(3) –OH,
(4) -OC_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,
(5) C_{4-7}cycloalkyloxy-, unsubstituted or substituted with one to two R^c substituents,
(6) C_{4-7}cycloalkyl-C_{1-3}alkyloxy-, unsubstituted or substituted with one to two R^c substituents,
(7) phenyloxy, unsubstituted or substituted with one to two R^c substituents,
(8) pyridyloxy, unsubstituted or substituted with one to two R^c substituents,
(9) phenyl-C_{1-3}alkyloxy, unsubstituted or substituted with one to two R^c substituents,
(10) pyridyl-C_{1-3}alkyloxy, unsubstituted or substituted with one to two R^c substituents,
(11) -NR^aR^b, wherein:

R^a is selected from:

(a) hydrogen,
(b) C_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,
(c) cycloalkyl, unsubstituted or substituted with one to two R^c substituents,
(d) cycloalkyl-C_{1-4}alkyl, unsubstituted or substituted with one to two R^c substituents,

(e) phenyl, unsubstituted or substituted with one to two R^c substituents,
(f) heteroaryl, unsubstituted or substituted with one to two R^c substituents,
(g) benzyl, unsubstituted or substituted with one to two R^c substituents,

R^b is selected from:

(a) hydrogen,
(b) C_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,

or

R^a and R^b together with the nitrogen atom to which they are attached form a bridged or unbridged heterocyclic ring of 4 to 7 members, unsubstituted or substituted on carbon with one to two R^c substitutents,

(12) -NHC(O)R^a, wherein:

R^a is selected from:

(a) hydrogen,
(b) C_{1-6}alkyl, unsubstituted or substituted with one to three R^c substituents,
(c) cycloalkyl, unsubstituted or substituted with one to two R^c substituents,
(d) cycloalkyl-C_{1-4}alkyl, unsubstituted or substituted with one to two R^c substituents,
(e) phenyl, unsubstituted or substituted with one to two R^c substituents,
(f) pyridyl, unsubstituted or substituted with one to three R^c substituents,
(g) benzyl, unsubstituted or substituted with one to two R^c substituents,
(h) pyridylmethyl-, unsubstituted or substituted with one to three R^c substituents,

(13) cyano, and
(14) $-SO_2C_{1-6}$alkyl, unsubstituted or substituted with one to three R^c substituents;

and pharmaceutically acceptable salts thereof.

8. The compound according to Claim 1, wherein:

R^1 is selected from:

(1) methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert.-butyl, n-pentyl, or 2,2-dimethylpropyloxy,
(2) –OH,
(3) methoxy, ethyloxy, isopropyloxy, n-butyloxy, sec-butyloxy, isobutyloxy, tert.-butyloxy, n-pentyloxy, or 2,2-dimethylpropyloxy, unsubstituted or substituted with one to three halo, hydroxy, or methoxy substituents,

(4) cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, or cycloheptyloxy,

(5) cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, or cycloheptylmethoxy,

(6) 4-fluorophenyloxy, 4-chlorophenyloxy, 4-methoxyphenyloxy, 3-fluorophenyloxy, 3-chlorophenyloxy, 3,4-difluorophenyloxy, 3,4-dichlorophenyloxy, 3,5-difluorophenyloxy, 3,5-dichlorophenyloxy or phenyloxy,

(7) 4-pyridyloxy, 3-pyridyloxy, 2-pyridyloxy, 6-chloro-3-pyridyloxy, or 5-chloro-3-pyridyloxy,

(8) benzyloxy, 3-fluorobenzyloxy, 3-chlorobenzyloxy, 4-fluorobenzyloxy, 4-chlorobenzyloxy, 3,4-difluorobenzyloxy, 3,4-dichlorobenzyloxy, 3,5-difluorobenzyloxy, 3,5-dichlorobenzyloxy, 2,4-fluorobenzyloxy, 2,4-dichlorobenzyloxy, alpha-methyl-4-fluorobenzyloxy, alpha-methyl-4-chlorobenzyloxy, alpha,alpha-dimethyl-4-fluorobenzyloxy, or alpha,alpha-dimethyl-4-chlorobenzyloxy,

(9) 2-pyridylmethyloxy 3,-pyridylmethyloxy, or 4-pyridylmethyloxy,

(10) amino, N-methylamino, N,N-dimethyamino, N,N-diisopropylamino, or -$N(CH_3)CH_2CH_2N(CH_3)_2$, or N-containing heterocycloalkyl bonded via nitrogen selected from: morpholinyl, thiomorpholinyl, pyrrolidnyl, piperidinyl, and [2.2.1]azabicycloheptyl,

(11) $-NHCOR^a$ wherein R^a is selected from:

(12) hydrogen,

(13) C_{1-4}alkyl,

(14) C_{4-6}cycloalkyl, and

(15) phenyl, 4-fluorophenyl, 4-chlorophenyl, 3,4-difluorophenyl, or 3,4-dichlorophenyl,

(16) $-CO_2H$,

(17) $-C(O)NH_2$,

(18) -CN,

(19) $-SCH_3$, and

(20) $-SO_2CH_3$;

R^2 is selected from:

(1) hydrogen,

(2) methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert.-butyl, n-pentyl, or 2,2-dimethylpropyloxy,

(3) –OH,

(4) methoxy, ethyloxy, isopropyloxy, n-butyloxy, sec-butyloxy, isobutyloxy, tert.-butyloxy, n-pentyloxy, or 2,2-dimethylpropyloxy, unsubstituted or substituted with one to three halo, hydroxy, or methoxy substituents,

(5) cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, or cycloheptyloxy,

(6) cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, or cycloheptylmethoxy,

(7) 4-fluorophenyloxy, 4-chlorophenyloxy, 3-fluorophenyloxy, 3-chlorophenyloxy, 3-cyanophenyloxy, 3,4-difluorophenyloxy, 3,4-dichlorophenyloxy, 3,5-difluorophenyloxy, 3,5-dichlorophenyloxy, or phenyloxy,

(8) benzyloxy, 3-fluorobenzyloxy, 3-chlorobenzyloxy, 4-fluorobenzyloxy, 4-chlorobenzyloxy, 3,4-difluorobenzyloxy, 3,4-dichlorobenzyloxy, 3,5-difluorobenzyloxy, 3,5-dichlorobenzyloxy, 2,4-fluorobenzyloxy, or 2,4-dichlorobenzyloxy,

(9) 4-pyridyloxy, 3-pyridyloxy, 2-pyridyloxy, 6-chloro-3-pyridyloxy, or 5-chloro-3-pyridyloxy,

(10) amino, N-methylamino, N-ethylamino, N,N-dimethyamino, N,N-diethylamino,N,N-diisopropylamino, or N-containing heterocycloalkyl bonded via nitrogen selected from: pyrrolidinyl, and piperidinyl,

(11) –NHCOR^a wherein R^a is selected from:

(12) hydrogen, and

(13) C_{1-4}alkyl,

(14) -CN, and

(15) $-SO_2CH_3$;

R^3 and R^4 are each independently selected from:

(1) 4-chlorophenyl,

(2) 4-methoxyphenyl,

(3) 4-fluorophenyl,

(4) 4-trifluoromethylphenyl,

(5) 3-chlorophenyl,

(6) 3-methoxyphenyl,

(7) 2,4-dichlorophenyl, and

(8) 2-chloro-4-methylthiophenyl;

and pharmaceutically acceptable salts thereof.

9. The compound according to Claim 8, wherein:
R^3 is 4-chlorophenyl and R^4 is 2,4-dichlorophenyl, and pharmaceutically acceptable salts thereof.

10. The compound according to Claim 1, selected from:
(1) 2-(4-fluorobenzyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(2) 2-(4-fluorobenzyloxy)-4-(2-chloro-4-methylthiophenyl)-5-(4-chlorophenyl)-pyrimidine;
(3) 2-(3,4-difluorobenzyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(4) 2-(3,4-difluorobenzyloxy)-4-(2-chloro-4-methylthio-phenyl)-5-(4-chlorophenyl)-pyrimidine;
(5) 2-(4-chlorobenzyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(6) 2-(4-chlorobenzyloxy)-4-(2-chloro-4-methylthio-phenyl)-5-(4-chlorophenyl)-pyrimidine;
(7) 2-(3,4-dichlorobenzyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(8) 2-(3,4-dichlorobenzyloxy)-4-(2-chloro-4-methylthio-phenyl)-5-(4-chlorophenyl)-pyrimidine;
(9) 2-(3-fluorobenzyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(10) 2-(3-fluorobenzyloxy)-4-(2-chloro-4-methylthio-phenyl)-5-(4-chlorophenyl)-pyrimidine;
(11) 2-(3-chlorobenzylamino)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-pyrimidine;
(12) 2-(n,n-dimethylamino)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine ;
(13) 2-amino-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(14) 2-carboxy-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(15) 2-methylthio-4-(3,4-difluorobenzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(16) 2-methylthio-4-hydroxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-pyrimidine; 2-methoxy-4-hydroxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(18) 2,4-dihydroxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(19) 2-methylthio-4-hydroxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(20) 2-(3,4-difluorobenzyloxy)-4-hydroxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(21) 2-(3,4-difluorobenyloxy)-4-hydroxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(22) 2,4-bis-(3,4-difluorobenyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(23) 2,4-dimethoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(24) 2,4-diethoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(25) 2,4-diisopropoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(26) 2-methylsulfonyl-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(27) 2,4-bis(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(28) 2-cyano-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(29) 2-(3,4-difluorobenzyloxy)-4-cyano-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(30) 2-cyano-4-(3,4-difluorobenzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(31) 2,4-bis(cyano)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(32) 2-(3,4-difluorophenoxy)-4-methyl-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(33) 2-ethyl4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(34) 2-isopropy-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(35) 2-(3,4-difluorobenzyloxy)-4-methyl-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(36) 2-(3,4-difluorobenzyloxy)-4-ethyl-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(37) 2-(3,4-difluorobenzyloxy)-4-(n-methylamino)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(38) 2-(3,4-difluorophenoxy)-4-amino-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(39) 2-(3,4-difluorobenzyloxy)-4-(amino)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(40) 2-(3,4-difluorophenoxy)-4-(acetylamino)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(41) 2-(3,4-difluorobenzyloxy)-4-(acetylamino)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(42) 2-(3,4-difluorophenoxy)-4-(n-pyrrolidinyl)-5-[4-chlorophenyl]-6-[2,4-dichlorophenyl]pyrimidine;
(43) 2-(cyclopropylmethoxy)-4-(n-pyrrolidinyl)-5-[4-chlorophenyl]-6-[2,4-dichlorophenyl]pyrimidine;
(44) 2-(n,n-diethylamino)-4-(3,4-difluorobenzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(45) 2-(n,n-diisopropylamino)-4-(3,4-difluorobenzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(46) 2-(n-pyrrolidyl)-4-(3,4-difluorobenzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(47) 2-(n-piperidyl)-4-(3,4-difluorobenzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(48) 2-(n-morpholinyl)-4-(3,4-difluorobenzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(49) 2-(7-n-[221]-azabicycloheptyl)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(50) 2-(n-propionyl)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(51) 2-(n-(2-methyl)propionyl)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(52) 2-(n-(3-methyl)butyryl)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(53) 2-(aminocarbonyl)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(54) 2-(carboxy)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(55) 2-(2-hydroxyethyleneoxy)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(56) 2-(2-methoxyethyleneoxy)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(57) 2-(cyclohexylmethyloxy)-4-isopropoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(58) 2-cyclohexyloxy-4-isopropoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(59) 2-(3,4-difluorophenoxy)-4-cyclohexyloxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(60) 2-(3,4-difluorobenzyloxy)-4-cyclohexyloxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(61) 2,4-bis(cyclopropylmethyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(62) 2-cyclopropyloxy-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(63) 2-(n-pyrrolidinyl)-4-cyclopropyloxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(64) 2,4-bis(isopropyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(65) 2-(3,4-difluorobenzyloxy)-4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)pyrimidine;

(66) 2-(4-chlorobenzyloxy)-4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)pyrimidine;

(67) 2-(3-fluorobenzyloxy)-4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)pyrimidine;

(68) 2-(3-chlorobenzyloxy)-4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)pyrimidine;

(69) 2-(4-fluorobenzyloxy)-4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)pyrimidine;
(70) 2-(α-methyl-4-fluorobenzyloxy-)-4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)pyrimidine;
(71) 2-(α-methyl-4-fluorobenzyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(72) 2-(3-pyridylmethoxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(73) 2-(n-butyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(74) 2-(2,4-dichlorobenzyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(75) 2-(cyclohexylmethoxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(76) 2-(3,5-dichlorobenzyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(77) 2-(6-chloro-3-pyridylmethoxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(78) 2-(α,α-dimethyl-4-fluorobenzyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(79) 2-(4-fluorophenyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(80) 2-(3-fluorophenyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(81) 2-(3,4-difluorophenyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(82) 2-(3-chlorophenyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(83) 2-(4-methoxyphenyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(84) 2-(3-pyridyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(85) 2-(5-chloro-3-pyridyloxy)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(86) 2-(n-(4-fluorobenzamido))-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(87) 2-(n-(cyclohexylcarboxamido))-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine;
(88) 2,4-bis(cyclobutylmethoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(89) 2-cyclobutylmethoxy-4-(6-fluoro-3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(90) 2-cyclobutylmethoxy-4-(5-chloro-3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(91) 2-methylsulfonyl-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(92) 2-cyclobutylmethoxy-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(93) 2-(2,2-dimethylpropyloxy)-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(94) 2-(2-t-butyloxy)-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(95) 2-(2-cyclobutyloxy)-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(96) 2-(n-propyloxy)-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(97) 2-(n-butyloxy)-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(98) 2-(sec-butyloxy)-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(99) 2-(iso-butyloxy)-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(100) 2-(isopropyloxy)-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(101) 2-(n-pentyloxy)-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(102) 2-cyclopropyloxy-4-(4-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(103) 2,4-bis-(4-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(104) 2-(isobutyloxy)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(105) 2-(cyclopropylmethoxy)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(106) 2-(isopropyloxy)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(107) 2-ethoxy-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(108) 2-(n-pyrrolidinyl)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(109) 2-(n,n',n'-trimethyl-ethylenediamino)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(110) 2-(n-piperidyl)-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(111) 2-(n-morpholinyl)-ethylenediamino-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(112) 2-dimethylamino-4-(3,4-difluorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(113) 2-(n-pyrrolidinyl)-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(114) 2-methylsulfonyl-4-(2-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(115) 2-(2-isopropyloxy)-4-(2-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(116) 2-(2-trimethyldiaimoloxy)-4-(2-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(117) 2-(2-pyrrolindyl)-4-(2-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(118) 2-(methylsulfonyl)-4-methoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(119) 2-methoxy-4-(methylsulfonyl)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(120) 2-(3,4-difluorophenyloxy)-4-methoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(121) 2-methoxy-4-(3,4-difluorophenyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(122) 2-(3-fluorophenyloxy)-4-methoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(123) 2-methoxy-4-(3-fluorophenyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(124) 2-methoxy-4-(2-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(125) 2-(2-pyridyloxy)-4-methoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(126) 2-(5-chloro-3-pyridyloxy)-4-methoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(127) 2-methoxy-4-(5-chloro-3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(128) 2-(3-pyridyloxy)-4-methoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(129) 2-methoxy-4-(3-pyridyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(130) 2-methoxy-4-(4-fluorophenyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(131) 2-methoxy-4-(3,5-difluorophenyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(132) 2-methoxy-4-(3-cyanophenyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(133) 2-(3,4-difluorobenzyloxy)-4-methoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(134) 2-methoxy-4-(3,4-difluorobenzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(135) 2-(methylsulfonyl)-4-ethoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(136) 2-ethoxy-4-(methylsulfonyl)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(137) 2-(3,4-difluorobenzyloxy)-4-ethoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(138) 2-ethoxy-4-(3,4-difluorophenyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(139) 2-(methylsulfonyl)-4-isopropyloxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(140) 2-isopropyloxy-4-(methylsulfonyl)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(141) 2-(3,4-difluorobenzyloxy)-4-isopropyloxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;

(142) 2-isopropyloxy-4-(3,4-difluorophenyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(143) 2-(3,4-difluorobenzyloxy)-4-pyrrolidinyl-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(144) 2-(3,4-difluorobenzyloxy)-4-diethylamino-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine; and
(145) 2-(3,4-difluorobenzyloxy)-4-dimethylamino-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidine;
(146) 2-(3,4-difluorophenoxy)-4-methoxy-5-(4-fluorophenyl)-6-[2, 4-dichlorophenyl]pyrimidine;
(147) 2-(3,4-difluorophenoxy)-4-methoxy-5-(4-methoxyphenyl)-6-[2, 4-dichlorophenyl]pyrimidine;
(148) 2-(3,4-difluorophenoxy)-4-methoxy-5-(4-trifluoromethylphenyl)-6-[2, 4-dichlorophenyl]pyrimidine;
(149) 2-(3,4-difluorophenoxy)-4-methoxy-5-(3-chlorophenyl)-6-[2, 4-dichlorophenyl]pyrimidine;
(150) 2-(3,4-difluorophenoxy)-4-methoxy-5-(3-methoxyphenyl)-6-[2, 4-dichlorophenyl]pyrimidine.

and pharmaceutically acceptable salts thereof.

11. A method of treating a disease mediated by the Cannabinoid-1 receptor comprising administration to a patient in need of such treatment of a therapeutically effective amount of a compound according to Claim 1.

12. The method according to Claim 11 wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, schizophrenia, substance abuse disorders, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, asthma, obesity, and other eating disorders associated with excessive food intake.

13. The method according to Claim 12 wherein the disease mediated by the Cannabinoid-1 receptor is an eating disorder associated with excessive food intake.

14. The method according to Claim 13 wherein the eating disorder asssociated with excessive food intake is selected from obesity, bulimia nervosa, and compulsive eating disorders.

15. The method according to Claim 14 wherein the eating disorder associated with excessive food intake is obesity.

16. A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.001 mg to about 100 mg per kg of a compound according to Claim 1.

17. A composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.

18. The use of a compound according to Claim 1,
for the manufacture of a medicament useful for the treatment of a disease mediated by the Cannabinoid-1 receptor in a human patient in need of such treatment.

19. The use according to Claim 18 wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, schizophrenia, substance abuse disorders, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, asthma, obesity, and other eating disorders associated with excessive food intake.

20. The use according to Claim 19 wherein the disease mediated by the Cannabinoid-1 receptor is an eating disorder associated with excessive food intake.

21. The use according to Claim 20, wherein the eating disorder asssociated with excessive food intake is selected from obesity, bulimia nervosa, and compulsive eating disorders.

22. The use according to Claim 21 wherein the eating disorder associated with excessive food intake is obesity.

23. The use of a compound according to Claim 1 for the manufacture of a medicament for the prevention of obesity in a person at risk therefor.